UroGen Reports $68.0 Million in ZUSDURI Revenue for Third Quarter 2026

UroGen reported third-quarter 2026 revenue of $89.0 million, compared with $27.5 million a year earlier, and a net loss of $1.5 million. ZUSDURI revenue was $68.0 million, up 35% sequentially. The company also reported FDA acceptance of the UGN-103 NDA and outlined plans to advance its clinical pro…